CD2/CD28 initiated CD28 signaling on CD58 binding in the absence of B7 ligands.56 Given the wide expression of CD58 on tumor cells, they hypothesized that CD2/CD28 could provide an efficient way to activate CD28 signaling in TME but follow-up studies with modern preclinical approaches have not assessed the utility of this construct. The gene discussed is CD28; the disease is neoplasm.